It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Effective integration of DMPK science is essential to the rational progression of compounds through the drug discovery pipeline. DMPK insights clarify ADME properties, guide medicinal chemistry optimization, and support prediction of human pharmacokinetics. Rigorous evaluation of in vitro and in vivo data enables early identification of liabilities, strengths translational modelling, and improves the selection of compounds with optimal developability. By embedding DMPK strategy throughout discovery, teams can mitigate risk, refine compound design, and accelerate the advancement of high-quality candidates toward clinical development.
At Sygnature Discovery, our DMPK consultancy delivers early, continuous, and scientifically grounded input across the drug discovery pipeline, with strength during Hit Identification, Hit-to-Lead, and Lead Optimization.
We bring deep expertise in complex areas such as CNS drug discovery and emerging modalities including heterobifunctional degraders and antibody-drug conjugates.
We guide compound selection and screening cascade design with attention to bioavailability, exposure, and metabolic stability, and we proactively identify and mitigate ADME and pharmacokinetic liabilities to improve downstream success. Through tailored consultancy, we help shape discovery programs that are scientifically robust and strategically aligned for clinical advancement.
Independent DMPK Review and Strategic Problem Solving to Strengthen Discovery Programs
Our independent DMPK consultancy supports in-licensing, out-licensing, and investment opportunities. We provide objective, science-driven reviews of DMPK data packages to identify strengths, limitations, and risks that may impact compound viability or development trajectory.
Combining pharmacokinetic expertise with commercial insight, we enable confident decision making, whether assessing assets for acquisition, preparing candidates for partnering, or validating investment potential. By highlighting ADME and PK liabilities early and placing findings in the broader development context, we align strategic choices with long-term success.
Independent DMPK Due Diligence to Inform Strategic Investment and Licensing Decisions
Our independent DMPK consultancy provides unbiased scientific oversight and strategic input at key decision points. We deliver expert reviews of discovery-stage projects and research proposals to ensure that DMPK considerations are rigorously evaluated before experimental investment. These assessments identify potential ADME and PK risks early and lead to data-driven recommendations that strengthen project robustness and translational potential.
When challenges arise, our scientists apply deep domain expertise and practical problem-solving to deliver tailored solutions, whether addressing poor bioavailability, suboptimal exposure, or complex metabolic liabilities. The approach is clear and constructive. If an experiment does not perform as expected, we explain what the data shows and outline practical alternatives with the best option highlighted for the next cycle.
Why Choose Sygnature Discovery for DMPK Consultancy Support?
Sygnature Discovery’s DMPK consultancy offers scientific insight and strategic support across the full spectrum of drug discovery and development. We have advanced more than 60 drug candidates into clinical development across pharma, biotech, CROs, and academia, reflecting deep cross-sector expertise and therapeutic breadth.
We embed DMPK strategy from early discovery stages, from Hit Identification through Lead Optimization, shaping compound selection, refining screening cascades, and anticipating development risks. This consultancy is especially valuable in complex domains such as CNS discovery, degraders, and ADCs.
In addition to program support, we deliver independent, third-party DMPK due diligence for licensing and investment decisions. Our objective assessments highlight key strengths, liabilities, and translational risks, enabling confident decision-making for asset acquisition, partnering, or market preparation.
Sygnature Discovery is attending SLAS2026 in Boston. Meet our Bioscience, DMPK and Physical Sciences experts as they share practical insight across early discovery and lead pre‑clinical drug discovery workshops onsite.
Sygnature Discovery, in collaboration with Iktos, presents a poster outlining the…
Posters
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
